| Literature DB >> 26617650 |
Dong Hyun Lee1, Sun Young Choi1, Jong Sung Park1, Jeong-Min Seo1, Jae-Hyuk Choi1, Young-Rak Cho1, Kyungil Park1, Moo Hyun Kim1, Young-Dae Kim1.
Abstract
BACKGROUND AND OBJECTIVES: Previous studies have evaluated atrial electromechanical delays (AEMDs) with a number of different definitions to discriminate patients with paroxysmal atrial fibrillation (PAF) from controls without PAF. However, their discriminative values for PAF have not previously been directly compared. SUBJECTS AND METHODS: A total of 65 PAF patients and 130 control subjects matched for age, sex, history of hypertension, and diabetes mellitus were selected. The AEMDi and AEMDp were defined as the time intervals from the initiation of the P wave on the surface electrocardiogram to the initiation and peak of the late diastolic transmitral inflow on pulsed wave Doppler images, respectively. The AEMDim and AEMDpm were defined as the time intervals from the initiation of the P wave on the surface electrocardiogram to the initiation and peak of the late diastolic lateral mitral annular motion on tissue Doppler images, respectively.Entities:
Keywords: Atrial fibrillation; Echocardiography; Electrocardiography
Year: 2015 PMID: 26617650 PMCID: PMC4661363 DOI: 10.4070/kcj.2015.45.6.479
Source DB: PubMed Journal: Korean Circ J ISSN: 1738-5520 Impact factor: 3.243
Fig. 1Echocardiographic measurements of AEMDs. (A) The time intervals, from the P wave initiation on the surface electrocardiogram channel to the initiation and peak of the late diastolic transmitral inflow on pulse wave Doppler images, were defined as the AEMDi and AEMDp. (B) The time intervals, from the P wave initiation on the surface electrocardiogram channel to the initiation and peak of the late diastolic lateral mitral annular motion on tissue Doppler images, were defined as the AEMDim and AEMDpm. AEMD: atrial electromechanical delay.
Clinical characteristics of the study population
| PAF (n=65) | Control (n=130) | p | |
|---|---|---|---|
| Age (years) | 57±16 | 57±16 | 0.941 |
| Male sex | 39 (61) | 78 (61) | 1.000 |
| Body mass index (kg/m2) | 25±3 | 24±3 | 0.073 |
| Hypertension | 27 (42) | 54 (42) | 1.000 |
| Antihypertensive agent | |||
| Dihydropyridine CCB | 12 (19) | 17 (13) | 0.318 |
| Other agents | 18 (28) | 34 (27) | 0.818 |
| Diabetes mellitus | 7 (11) | 14 (11) | 1.000 |
| HbA1c (%) | 6.0±1.0 | 5.6±0.7 | 0.107 |
| CHADS2 score | 0.7±0.8 | 0.6±0.8 | 0.510 |
| Systolic BP (mmHg) | 123±13 | 124±15 | 0.778 |
| Diastolic BP (mmHg) | 73±8 | 77±18 | 0.089 |
| Total cholesterol (mg/dL) | 184±37 | 188±44 | 0.481 |
| Estimated GFR (mL/min/1.73 m2) | 89±22 | 89±21 | 0.815 |
Data are presented as mean±standard deviation and n (%). PAF: paroxysmal atrial fibrillation, CCB: calcium channel blocker, HbA1c: hemoglobin A1c, BP: blood pressure, GFR: glomerular filtration rate
Electrocardiographic and echocardiographic parameters of the study population
| PAF (n=65) | Control (n=130) | p | |
|---|---|---|---|
| PR interval (ms) | 172±25 | 167±22 | 0.172 |
| RR interval (ms) | 984±177 | 961±124 | 0.364 |
| AEMDs | |||
| AEMDi (ms) | 73±16 | 53±10 | <0.001 |
| AEMDp (ms) | 146±22 | 134±18 | 0.001 |
| AEMDim (ms) | 80±22 | 63±17 | <0.001 |
| AEMDpm (ms) | 141±23 | 125±19 | <0.001 |
| P wave duration (ms) | 62±22 | 69±20 | 0.403 |
| P wave amplitude (µV) | 96±41 | 68±35 | <0.001 |
| Width of QRS complex (ms) | 94±13 | 95±15 | 0.604 |
| Bundle branch block | 6 (9) | 12 (9) | 1.000 |
| Ejection fraction (%) | 63±4 | 64±3 | 0.610 |
| LA volume index (mL/m2) | 35±11 | 29±10 | <0.001 |
| LV end diastolic dimension (mm) | 49±4 | 48±4 | 0.156 |
| LV mass index (g/m2) | 88±17 | 85±19 | 0.339 |
| LV hypertrophy* | 3 (5) | 8 (6) | 0.661 |
| Mitral E velocity (cm/sec) | 72±20 | 67±14 | 0.131 |
| Mitral A velocity (cm/sec) | 69±20 | 71±18 | 0.485 |
| Mitral E/A ratio | 1.1±0.5 | 1.0±0.4 | 0.106 |
| Mitral e' velocity (cm/sec) | 10±7 | 9±3 | 0.106 |
| E/e' ratio >15 | 4 (6) | 8 (6) | 0.989 |
Data are presented as mean±standard deviation and n (%). PAF: paroxysmal atrial fibrillation, AEMD: atrial electromechanical delay, LA: left atrium, LV: left ventricle. *Left ventricular hypertrophy was defined as the echocardiographically measured left ventricular mass index greater than 115 g/m2 for males and 95 g/m2 for females
The values of area under the curve for electrocardiographic and echocardiographic parameters
| AUC values | 95% CI | p | p* | |
|---|---|---|---|---|
| AEMDi (ms) | 0.851±0.033 | 0.787-0.916 | <0.001 | - |
| AEMDp (ms) | 0.678±0.042 | 0.595-0.762 | <0.001 | 0.0012 |
| AEMDim (ms) | 0.743±0.039 | 0.666-0.819 | <0.001 | 0.0345 |
| AEMDpm (ms) | 0.718±0.040 | 0.369-0.796 | <0.001 | 0.0103 |
| LAVI (mL/m2) | 0.703±0.039 | 0.627-0.779 | <0.001 | 0.0038 |
| P-amplitude (µV) | 0.703±0.038 | 0.628-0.778 | <0.001 | 0.0033 |
Data are presented as mean±standard deviation. AUC: area under the curve, CI: confidence interval, AEMD: atrial electromechanical delay, LAVI: left atrial volume index, P-amplitude: P wave amplitude. *p for AEMDi vs. other parameters. There were no significant differences between AEMDp, AEMDim, AEMDpm, LAVI, and P wave amplitude